908 Devices Inc. (MASS)
| Market Cap | 364.32M +54.5% |
| Revenue (ttm) | 57.80M +10.9% |
| Net Income | -36.07M |
| EPS | -0.99 |
| Shares Out | 41.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 322,937 |
| Open | 8.37 |
| Previous Close | 8.30 |
| Day's Range | 8.30 - 8.88 |
| 52-Week Range | 5.03 - 9.34 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+23.87%) |
| Earnings Date | Aug 11, 2026 |
About MASS
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MASS stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 23.87% from the latest price.
News
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices initiated with a Buy at Roth Capital
Roth Capital initiated coverage of 908 Devices (MASS) with a Buy rating and $11 price target The firm views 908 as a “high-quality, pure-play” handheld chemical detection company that provides…
908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Transcript: 16th Annual East Coast IDEAS Conference
The company has transformed into a focused provider of handheld chemical detection devices, achieving strong revenue growth, improved margins, and a diversified customer base. Recent acquisitions, product innovation, and a shift toward recurring software revenue position it for continued expansion and profitability.
908 Devices Slides: 16th Annual East Coast IDEAS Conference
908 Devices has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices price target raised to $10 from $8 at Stifel
Stifel raised the firm’s price target on 908 Devices (MASS) to $10 from $8 and keeps a Buy rating on the shares.
908 Devices completes acquisition of NIRLAB AG
908 Devices (MASS) announced that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared...
908 Devices reports Q1 EPS (32c), consensus (14c)
Reports Q1 revenue $13.4M, consensus $13.16M. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are…
908 Devices raises FY26 revenue view to $67M-$70M from $64.5M-$67.5M
Consensus $65.94M.
908 Devices Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 14% year-over-year, driven by strong handheld sales and recurring revenue. The NIRLAB acquisition expands international reach and accelerates software-driven recurring revenue, supporting raised 2026 guidance and a path to profitability in 2027.
908 Devices Earnings release: Q1 2026
908 Devices released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
908 Devices Slides: Q1 2026
908 Devices has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
908 Devices Quarterly report: Q1 2026
908 Devices has published its Q1 2026 quarterly earnings report on May 6, 2026.
908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ChemicalID--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety an...
908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio
BURLINGTON, Mass.--(BUSINESS WIRE)-- #LawEnforcement--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisitio...
908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Proxy statement: Proxy filing
908 Devices filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
908 Devices Proxy statement: Proxy filing
908 Devices filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
908 Devices names Kola Otitoju as Chief Business & Strategy Officer
908 Devices (MASS) announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Otitoju will oversee product and corporate strategy, business...
908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business ...
908 Devices Transcript: Sidoti March Small-Cap Virtual Conference
The company completed a strategic transformation, focusing on handheld analytical devices and expanding its product suite, including the innovative VipIR and XplorIR. Strong financial performance in 2025, recurring revenue growth, and operational improvements position the business for 15%-20% revenue growth in 2026 and sustainable profitability in the coming years.
908 Devices to Present at the Sidoti Small Cap Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Transcript: Leerink Global Healthcare Conference 2026
Demand is rising due to global unrest, increased defense spending, and secular trends in chemical detection. Financial performance exceeded guidance, with strong state and local sales, and a path to profitability by 2027. Product innovation and international expansion remain key growth drivers.